296 related articles for article (PubMed ID: 28893920)
1. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Pecoits-Filho R; Perkovic V
Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
[No Abstract] [Full Text] [Related]
2. Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.
Tuttle KR; Cherney DZ;
Clin J Am Soc Nephrol; 2020 Feb; 15(2):285-288. PubMed ID: 31740570
[No Abstract] [Full Text] [Related]
3. Sweet success? SGLT2 inhibitors and diabetes.
Layton AT
Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1034-F1035. PubMed ID: 29357429
[No Abstract] [Full Text] [Related]
4. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney.
Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Garofalo C; Chiodini P; Ceriello A; Esposito K
Cardiovasc Diabetol; 2020 Mar; 19(1):35. PubMed ID: 32192503
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
6. Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
Kobayashi K; Toyoda M; Kaneyama N; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Miyakawa M
J Diabetes Res; 2019; 2019():9415313. PubMed ID: 31781668
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
[TBL] [Abstract][Full Text] [Related]
10. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
[TBL] [Abstract][Full Text] [Related]
12. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
14. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
Kume S; Packer M
Kidney Int; 2024 Jun; 105(6):1172-1176. PubMed ID: 38777403
[No Abstract] [Full Text] [Related]
16. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
MacIsaac RJ; Thomas MC
Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
[No Abstract] [Full Text] [Related]
17. Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
Hallow KM; Boulton DW; Penland RC; Helmlinger G; Nieves EH; van Raalte DH; Heerspink HL; Greasley PJ
J Pharmacol Exp Ther; 2020 Oct; 375(1):76-91. PubMed ID: 32764153
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database.
Kanaoka T; Wakui H; Yano Y; Nagasu H; Kanegae H; Nangaku M; Hirakawa Y; Nakagawa N; Wada J; Tsuruya K; Nakano T; Maruyama S; Wada T; Konishi M; Nagahiro T; Yamagata K; Narita I; Yanagita M; Terada Y; Araki S; Emoto M; Okada H; Isaka Y; Suzuki Y; Yokoo T; Kataoka H; Kanda E; Kashihara N; Tamura K;
Diabetes Obes Metab; 2024 Jul; 26(7):2905-2914. PubMed ID: 38719436
[TBL] [Abstract][Full Text] [Related]
19. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
Lanthier L; Huard G; Plourde MÉ; Cauchon M
Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
[No Abstract] [Full Text] [Related]
20. The landscape of diabetic kidney disease transformed.
Tuttle KR
Nat Rev Nephrol; 2020 Feb; 16(2):67-68. PubMed ID: 31831876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
